

June 15, 2016



# Actinium Sponsored Acute Myeloid Leukemia (AML) Awareness Month Continues With Medical Update Webinar

NEW YORK, NY -- (Marketwired) -- 06/15/16 --

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM)

- Webinar to Be Held on Friday, June 17, 2016 Featuring Thought Leaders in the Field of AML
- John Pagel, M.D., Ph.D., Actinium Advisory Board Member, to Discuss Bone Marrow Transplant as a Treatment Option for Patients With AML

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of patients with advanced cancers, announced today that a webinar focused on medical updates for AML will be hosted by CancerCare® as part of the first ever Acute Myeloid Leukemia (AML) Awareness Month.

**Event:** Medical Update on AML

**Date:** Friday, June 17, 2016

**Time:** 1:30 - 2:45 PM (Eastern Time)

**Webcast link:**[http://www.cancercare.org/connect\\_workshops/525-medical\\_update\\_aml\\_2016-06-17](http://www.cancercare.org/connect_workshops/525-medical_update_aml_2016-06-17)

The webinar will address the following topics:

- Overview of Acute Myelogenous Leukemia (AML)
- Current Treatment Options
- Transplantation as a Treatment Option for AML
- New Therapies
- The Role of Clinical Trials: How They Increase Your Treatment Options
- Symptom and Pain Management Tips
- Important Questions to Ask When Communicating with Your Health Care Team
- Quality-of-Life Concerns
- Questions for Our Panel of Experts

Sandesh Seth, Actinium's Executive Chairman, stated, "The first ever AML Awareness Month has been a huge success thus far with the efforts of CancerCare, Craig Sager and his family bringing much needed awareness to AML. The upcoming webinar should prove to be an excellent event for patients and their families that are battling AML as there is significant

efforts underway to develop new therapies for AML. We are excited that bone marrow transplant is included in the webinar program as it represents the only potentially curative option for many patients with AML and an area Actinium is acutely focused on as a result of our Iomab-B therapy, which is intended to prepare patients for a bone marrow transplant."

### ***About Cancer Care ®***

Founded in 1944, CancerCare is the leading national organization providing free, professional support services and information to help people manage the emotional, practical and financial challenges of cancer. CancerCare's comprehensive services include counseling and support groups over the phone, online and in-person, educational workshops, publications and financial and co-payment assistance. All CancerCare services are provided by oncology social workers and world-leading cancer experts. Headquartered in New York, NY, CancerCare maintains three additional locations in Norwalk, CT, Ridgewood, NJ and Syosset, NY.

To learn more, visit [www.cancercare.org](http://www.cancercare.org) or call 800-813-HOPE (4673).

### ***About Iomab-B***

Iomab-B is about to begin the pivotal, Phase 3 SIERRA trial and is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct the single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. Iomab-B is a radioimmunoconjugate consisting of BC8, a novel murine monoclonal antibody, and iodine-131 radioisotope. BC8 has been developed by the Fred Hutchinson Cancer Research Center to target CD45, a pan-leukocytic antigen widely expressed on white blood cells. This antigen makes BC8 potentially useful in targeting white blood cells in preparation for hematopoietic stem cell transplantation in a number of blood cancer indications, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), Hodgkin's disease (HD), Non-Hodgkin lymphomas (NHL) and multiple myeloma (MM). When labeled with radioactive isotopes, BC8 carries radioactivity directly to the site of cancerous growth and bone marrow while avoiding effects of radiation on most healthy tissues.

### ***About Actinium Pharmaceuticals***

Actinium Pharmaceuticals, Inc. ([www.actiniumpharma.com](http://www.actiniumpharma.com)) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy products are based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company's lead radiopharmaceutical product candidate Iomab-B is designed to be used, upon approval, in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company plans to conduct a single, pivotal, multicenter Phase 3 clinical study of Iomab-B in refractory and relapsed AML patients over the age of 55 with a primary endpoint of durable complete remission. The Company's second product candidate, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm

multicenter trial.

***Forward-Looking Statements for Actinium Pharmaceuticals, Inc.***

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Contact:

Actinium Pharmaceuticals

Steve O'Loughlin

Vice President, Finance and Corporate Development

Actinium Pharmaceuticals, Inc.

[soloughlin@actiniumpharma.com](mailto:soloughlin@actiniumpharma.com)

Source: Actinium Pharmaceuticals